康芝药业
(300086)
| 流通市值：32.61亿 | | | 总市值：33.68亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 96,573,833.91 | 466,122,703.87 | 326,382,078.2 | 232,448,515.1 |
| 营业收入 | 96,573,833.91 | 466,122,703.87 | 326,382,078.2 | 232,448,515.1 |
| 二、营业总成本 | 105,357,588.5 | 650,931,951.28 | 454,805,398.28 | 302,106,524.19 |
| 营业成本 | 38,085,327.99 | 213,477,662.16 | 152,213,016.72 | 107,540,967.99 |
| 税金及附加 | 3,754,922.08 | 14,196,986.73 | 9,630,336.01 | 5,940,538.16 |
| 销售费用 | 32,442,507.76 | 265,040,987.26 | 179,143,135.32 | 116,211,532.39 |
| 管理费用 | 23,980,751.69 | 121,232,452.63 | 84,675,602.99 | 55,341,975.52 |
| 研发费用 | 3,546,412.09 | 19,102,615.4 | 15,438,816.8 | 8,874,961.73 |
| 财务费用 | 3,547,666.89 | 17,881,247.1 | 13,704,490.44 | 8,196,548.4 |
| 其中:利息费用 | 3,531,840 | 17,865,052.16 | 12,696,141.63 | 8,324,962.66 |
| 其中:利息收入 | 20,836.79 | 222,601.67 | 192,861.48 | 184,450.19 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -37,040,780.83 | - | - |
| 加:投资收益 | - | 1,448,606.93 | - | - |
| 资产处置收益 | -1,281.41 | 473,746.05 | 469,410.71 | 455,864.28 |
| 资产减值损失(新) | 1,683,328.32 | -56,137,235.23 | 1,311,574.79 | -2,678,657.13 |
| 信用减值损失(新) | -356,805.17 | 11,873,348.84 | 9,937,505.59 | 7,441,671.98 |
| 其他收益 | 996,020.7 | 6,883,622.32 | 4,799,662.33 | 3,749,432.85 |
| 四、营业利润 | -6,462,492.15 | -257,307,939.33 | -111,905,166.66 | -60,689,697.11 |
| 加:营业外收入 | 145,132.15 | 693,931.27 | 453,992.16 | 378,746.6 |
| 减:营业外支出 | 70,614.8 | 2,858,141.59 | 385,513.6 | 307,914.32 |
| 五、利润总额 | -6,387,974.8 | -259,472,149.65 | -111,836,688.1 | -60,618,864.83 |
| 减:所得税费用 | 5,751,061.75 | -25,443,282.17 | -13,713,052.48 | -5,510,515.08 |
| 六、净利润 | -12,139,036.55 | -234,028,867.48 | -98,123,635.62 | -55,108,349.75 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -12,139,036.55 | -234,028,867.48 | -98,123,635.62 | -55,108,349.75 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -11,749,745.07 | -230,138,658.52 | -96,611,496.44 | -54,081,719.36 |
| 少数股东损益 | -389,291.48 | -3,890,208.96 | -1,512,139.18 | -1,026,630.39 |
| 扣除非经常损益后的净利润 | -11,895,517.57 | -203,008,509.18 | -98,634,570.11 | -56,007,110.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | -0.51 | -0.21 | -0.12 |
| (二)稀释每股收益 | -0.03 | -0.51 | -0.21 | -0.12 |
| 八、其他综合收益 | - | 14,335,824.51 | - | - |
| 归属于母公司股东的其他综合收益 | - | 14,335,824.51 | - | - |
| 九、综合收益总额 | -12,139,036.55 | -219,693,042.97 | -98,123,635.62 | -55,108,349.75 |
| 归属于母公司股东的综合收益总额 | -11,749,745.07 | -215,802,834.01 | -96,611,496.44 | -54,081,719.36 |
| 归属于少数股东的综合收益总额 | -389,291.48 | -3,890,208.96 | -1,512,139.18 | -1,026,630.39 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-27 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |